These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 16029810)

  • 1. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
    Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.
    Vosseler S; Mirancea N; Bohlen P; Mueller MM; Fusenig NE
    Cancer Res; 2005 Feb; 65(4):1294-305. PubMed ID: 15735015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of human cripto-1 in tumor angiogenesis.
    Bianco C; Strizzi L; Ebert A; Chang C; Rehman A; Normanno N; Guedez L; Salloum R; Ginsburg E; Sun Y; Khan N; Hirota M; Wallace-Jones B; Wechselberger C; Vonderhaar BK; Tosato G; Stetler-Stevenson WG; Sanicola M; Salomon DS
    J Natl Cancer Inst; 2005 Jan; 97(2):132-41. PubMed ID: 15657343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
    Zhang L; Hannay JA; Liu J; Das P; Zhan M; Nguyen T; Hicklin DJ; Yu D; Pollock RE; Lev D
    Cancer Res; 2006 Sep; 66(17):8770-8. PubMed ID: 16951193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
    Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
    Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
    Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
    Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
    Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
    Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
    Kozin SV; Boucher Y; Hicklin DJ; Bohlen P; Jain RK; Suit HD
    Cancer Res; 2001 Jan; 61(1):39-44. PubMed ID: 11196192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
    Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
    Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
    Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
    Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.